干眼症的药物治疗策略及研究进展  

Drug treatment strategy and research progress of dry eye disease

作　　者：秦红倩 许卉[1] QIN Hong-qian;XU Hui(YanTai University,Yantai 264000,China)

机构地区：[1]烟台大学,山东烟台264000

出　　处：《中国处方药》2024年第2期168-170,共3页Journal of China Prescription Drug

摘　　要：干眼症(DED)是一种复杂的多因素疾病,表现出不同的症状,这些症状可影响视觉功能,导致日常生活活动受限,工作效率降低,从而严重影响生活质量。本综述对目前临床上DED的治疗药物以及市场上正在开发的DED治疗策略进行总结,旨在对临床研究提供参考。Dry eye disease(DED)is a complex and multifactorial disease with different symptoms.These symptoms can affect visual function,resulting in limited activities of daily living and reduced work efficiency,thus seriously affecting the quality of life.This review provides a summary of the current clinical therapeutic drugs for DED and the developing therapeutic strategies for DED in the market,aiming to provide a reference for clinical research.

关 键 词：干眼症 治疗策略 人工泪液 非甾体抗炎药 Tivanisiran IL-1R拮抗剂 EBI-005 

分 类 号：R777.34[医药卫生—眼科]